FDA drug approvals slow down in 2026 under interim leadership

Under interim FDA leadership, regulatory decisions on drug approvals will face delays or unpredictability in 2026, with key vacancies in drug and biologics centers persisting. This will create additional uncertainty for pharmaceutical investors.

Implied probability (Yes)

80%